Movement Disorders Program

Movement Disorders Program

The Movement Disorders Program evaluates, diagnoses, and treats all movement disorders including:

• Tremors
• Parkinson’s disease
• Dystonia
• Restless leg syndrome
• Huntington’s disease or chorea

Dr. Christopher Way is a movement disorders specialist that performs deep brain stimulation programming for Parkinson’s disease and essential tremor and performs botulinum toxin injections for dystonia.

Dr. Way is the principal investigator of the PROSEEK study at Renown. PROSEEK is a drug trial that is studying a c-Abl inhibitor developed by SUN pharmaceuticals that has shown promise in slowing the progression of Parkinson’s disease. To be a candidate for the study, one must fulfill at least the following criteria:

• Age > 50 years
• Diagnosed with Parkinson’s disease within the last 3 years
• Not on medication for treatment of Parkinson’s disease aside from monoamine oxidase B (MAOB) inhibitors.

If you fulfill the above criteria and wish to receive more information about the study, please fill out this form.

The PROSEEK Study is a clinical research study evaluating a once-daily, oral investigational drug for people with early-stage Parkinson’s disease (PD). The investigational drug is designed to block a specific enzyme called “Abl.” Research has shown that overactivation of Abl may play a role in PD progression. Therefore, by limiting or blocking Abl, it may be possible to help to slow PD progression.